Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - cellcept
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp7864f63eceae865956b53410a93ee1e9
identifier: http://ema.europa.eu/identifier
/EU/1/96/005/001 CellCept
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: CellCept 250 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-7864f63eceae865956b53410a93ee1e9
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/96/005/001 CellCept
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - cellcept
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
CellCept contains mycophenolate mofetil.
WARNING Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.
Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions. If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under Warnings and precautions and Pregnancy and breast-feeding .
Do not take CellCept:
Warnings and precautions
Talk to your doctor straight away before starting treatment with CellCept:
If any of the above apply to you (or you are not sure), talk to your doctor straight away before starting treatment with CellCept.
The effect of sunlight CellCept reduces your body s defences. As a result, there is an increased risk of skin cancer. Limit the amount of sunlight and UV light you get. Do this by:
Children Do not give this medicine to children younger than 2 years because based on the limited safety and efficacy data for this age group no dose recommendations can be made.
Other medicines and CellCept Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, such as herbal medicines. This is because CellCept can affect the way some other medicines work. Also other medicines can affect the way CellCept works. In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start CellCept:
Vaccines If you need to have a vaccination (a live vaccine) while taking CellCept, talk to your doctor or pharmacist first. Your doctor will have to advise you on what vaccines you can have.
You must not donate blood during treatment with CellCept and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with CellCept and for at least 90 days after stopping treatment.
CellCept with food and drink Taking food and drink has no effect on your treatment with CellCept.
Contraception in women taking CellCept If you are a woman who could become pregnant, you must use an effective method of contraception with CellCept. This includes:
You cannot become pregnant if any of the following conditions applies to you:
Contraception in men taking CellCept The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking CellCept.
If you are planning to have a child, talk to your doctor about the potential risks and alternative therapies.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if:
Pregnancy Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23 - 27%) in the unborn baby. Birth defects that have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed). Your baby may be affected by one or more of these.
If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.
Breast-feeding Do not take CellCept if you are breast-feeding. This is because small amounts of the medicine can pass into the mother s milk.
Driving and using machines CellCept has a moderate influence on your ability to drive or use any tools or machines. If you feel drowsy, numb or confused, talk to your doctor or nurse and do not drive or use any tools or machines until you feel better.
CellCept contains sodium This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much to take The amount you take depends on the type of transplant you have had. The usual doses are shown below. Treatment will continue for as long as you need to prevent rejection of your transplant organ.
Kidney transplant Adults
Heart transplant Adults
Liver transplant Adults
Taking the medicine Swallow your capsules whole with a glass of water
Take care not to let any powder from inside a broken capsule get into your eyes or mouth.
Take care not to let any powder from inside a broken capsule get onto your skin.
If you take more CellCept than you should If you take more CellCept than you should, talk to a doctor or go to a hospital straight away. Also do this if someone else accidentally takes your medicine. Take the medicine pack with you.
If you forget to take CellCept If you forget to take your medicine at any time, take it as soon as you remember. Then continue to take it at the usual times. Do not take a double dose to make up for a missed dose.
If you stop taking CellCept Do not stop taking CellCept unless your doctor tells you to. If you stop your treatment you may increase the chance of rejection of your transplant organ.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, CellCept can cause side effects, although not everybody gets them.
Talk to a doctor straight away if you notice any of the following serious side effects you may need urgent medical treatment:
Usual problems Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to check for any changes in:
Children may be more likely than adults to have some side effects. These include diarrhoea, infections, fewer white cells and fewer red cells in the blood.
Fighting infections CellCept reduces your body s defences. This is to stop you rejecting your transplant. As a result, your body will not be as good as normal at fighting infections. This means you may catch more infections than usual. This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system.
Lymph and skin cancer As can happen in patients taking this type of medicine (immune-suppressants), a very small number of patients on CellCept have developed cancer of the lymphoid tissues and skin.
General unwanted effects You may get general side effects affecting your body as a whole. These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle), headache, flu symptoms and swelling.
Other unwanted effects may include: Skin problems such as:
Urinary problems such as:
Digestive system and mouth problems such as:
Nervous system problems such as:
Heart and blood vessel problems such as:
Lung problems such as:
Other problems such as:
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
What CellCept contains
What CellCept looks like and contents of the pack
Marketing Authorisation Holder Roche Registration GmbH
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany
Manufacturer Roche Pharma AG, Emil-Barell-Str. 1, 79639 Grenzach Wyhlen, Germany.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien N.V. Roche S.A. T l/Tel: +32 (0) 2 525 82 Lietuva UAB Roche Lietuva
Tel: +370 5 2546
: +359 2 818 44 Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)
esk republika Roche s. r. o. Tel: +420 - 2 20382Magyarorsz g Roche (Magyarorsz g) Kft. Tel: +36 - 1 279 4Danmark Roche Pharmaceuticals A/S Tlf: +45 - 36 39 99 Malta (See Ireland)
Deutschland Roche Pharma AG Tel: +49 (0) 7624 Nederland Roche Nederland B.V. Tel: +31 (0) 348 438Eesti Roche Eesti O
Tel: + 372 - 6 177 Norge Roche Norge AS Tlf: +47 - 22 78 90
Roche (Hellas) A.E.
: +30 210 61 66 sterreich Roche Austria GmbH Tel: +43 (0) 1 27Espa a Roche Farma S.A. Tel: +34 - 91 324 81 Polska Roche Polska Sp.z o.o. Tel: +48 - 22 345 18 France Roche T l: +33 (0)1 47 61 40 Portugal Roche Farmac utica Qu mica, Lda Tel: +351 - 21 425 70 Hrvatska Roche d.o.o. Tel: + 385 1 47 22 Rom nia Roche Rom nia S.R.L. Tel: +40 21 206 47 Ireland Roche Products (Ireland) Ltd. Tel: +353 (0) 1 469 0Slovenija Roche farmacevtska dru ba d.o.o. Tel: +386 - 1 360 26 sland
Roche Pharmaceuticals A/S c/o Icepharma hf S mi: +354 540 8Slovensk republika
Roche Slovensko, s.r.o. Tel: +421 - 2 52638Italia Roche S.p.A. Tel: +39 - 039 2Suomi/Finland Roche Oy
Puh/Tel: +358 (0) 10 554 K
. . & . : +357 - 22 76 62 Sverige Roche AB Tel: +46 (0) 8 726 1Latvija Roche Latvija SIA Tel: +371 - 6 7039United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website:
http://www.ema.europa.eu
Package leaflet: Information for the user
CellCept 500 mg powder for concentrate for solution for infusion mycophenolate mofetil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet:
Entry 1 - fullUrl = Composition/composition-en-7864f63eceae865956b53410a93ee1e9
Resource Composition:
Generated Narrative: Composition composition-en-7864f63eceae865956b53410a93ee1e9
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/96/005/001 CellCeptstatus: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - cellcept
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp7864f63eceae865956b53410a93ee1e9
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp7864f63eceae865956b53410a93ee1e9
identifier:
http://ema.europa.eu/identifier
/EU/1/96/005/001 CellCepttype: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: CellCept 250 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en